Literature DB >> 23550968

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Radboud J Duintjer Tebbens1, Mark A Pallansch, Konstantin M Chumakov, Neal A Halsey, Tapani Hovi, Philip D Minor, John F Modlin, Peter A Patriarca, Roland W Sutter, Peter F Wright, Steven G F Wassilak, Stephen L Cochi, Jong-Hoon Kim, Kimberly M Thompson.   

Abstract

With the intensifying global efforts to eradicate wild polioviruses, policymakers face complex decisions related to achieving eradication and managing posteradication risks. These decisions and the expanding use of inactivated poliovirus vaccine (IPV) trigger renewed interest in poliovirus immunity, particularly the role of mucosal immunity in the transmission of polioviruses. Sustained high population immunity to poliovirus transmission represents a key prerequisite to eradication, but poliovirus immunity and transmission remain poorly understood despite decades of studies. In April 2010, the U.S. Centers for Disease Control and Prevention convened an international group of experts on poliovirus immunology and virology to review the literature relevant for modeling poliovirus transmission, develop a consensus about related uncertainties, and identify research needs. This article synthesizes the quantitative assessments and research needs identified during the process. Limitations in the evidence from oral poliovirus vaccine (OPV) challenge studies and other relevant data led to differences in expert assessments, indicating the need for additional data, particularly in several priority areas for research: (1) the ability of IPV-induced immunity to prevent or reduce excretion and affect transmission, (2) the impact of waning immunity on the probability and extent of poliovirus excretion, (3) the relationship between the concentration of poliovirus excreted and infectiousness to others in different settings, and (4) the relative role of fecal-oral versus oropharyngeal transmission. This assessment of current knowledge supports the immediate conduct of additional studies to address the gaps.
© 2013 Society for Risk Analysis.

Entities:  

Mesh:

Year:  2013        PMID: 23550968      PMCID: PMC7890644          DOI: 10.1111/risa.12031

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  46 in total

1.  Optimal vaccine stockpile design for an eradicated disease: application to polio.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; James P Alexander; Kimberly M Thompson
Journal:  Vaccine       Date:  2010-04-27       Impact factor: 3.641

2.  A structured expert judgment study for a model of Campylobacter transmission during broiler-chicken processing.

Authors:  H J Van der Fels-Klerx; Roger M Cooke; Maarten N Nauta; Louis H Goossens; Arie H Havelaar
Journal:  Risk Anal       Date:  2005-02       Impact factor: 4.000

3.  Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard Gary; James P Alexander; Linda Venczel; Denise Johnson; Victor M Cáceres; Nalinee Sangrujee; Hamid Jafari; Stephen L Cochi
Journal:  Risk Anal       Date:  2006-12       Impact factor: 4.000

Review 4.  Vaccination against polio should not be stopped.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld; Eckard Wimmer; Vadim I Agol
Journal:  Nat Rev Microbiol       Date:  2007-12       Impact factor: 60.633

5.  A delphi method expert survey to derive standards for flood damage data collection.

Authors:  Florian Elmer; Isabel Seifert; Heidi Kreibich; Annegret H Thieken
Journal:  Risk Anal       Date:  2009-12-11       Impact factor: 4.000

6.  Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated?

Authors:  M Eichner; K Dietz
Journal:  Am J Epidemiol       Date:  1996-04-15       Impact factor: 4.897

7.  Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.

Authors:  Roland W Sutter; T Jacob John; Hemant Jain; Sharad Agarkhedkar; Padmasani Venkat Ramanan; Harish Verma; Jagadish Deshpande; Ajit Pal Singh; Meghana Sreevatsava; Pradeep Malankar; Anthony Burton; Arani Chatterjee; Hamid Jafari; R Bruce Aylward
Journal:  Lancet       Date:  2010-10-25       Impact factor: 79.321

8.  Expert judgment-based risk assessment using statistical scenario analysis: a case study-running the bulls in Pamplona (Spain).

Authors:  Fermín Mallor; Carmen García-Olaverri; Sagrario Gómez-Elvira; Pedro Mateo-Collazas
Journal:  Risk Anal       Date:  2008-07-25       Impact factor: 4.000

9.  Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992-93.

Authors:  P M Oostvogel; J K van Wijngaarden; H G van der Avoort; M N Mulders; M A Conyn-van Spaendonck; H C Rümke; G van Steenis; A M van Loon
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

10.  Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.

Authors: 
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

View more
  42 in total

1.  Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Derek T Ehrhardt; Noha H Farag; Stephen C Hadler; Lee M Hampton; Maureen Martinez; Steve G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-01-03       Impact factor: 4.000

2.  Kinetics of poliovirus shedding following oral vaccination as measured by quantitative reverse transcription-PCR versus culture.

Authors:  Mami Taniuchi; Sharmin Begum; Md Jashim Uddin; James A Platts-Mills; Jie Liu; Beth D Kirkpatrick; Anwarul H Chowdhury; Khondoker M Jamil; Rashidul Haque; William A Petri; Eric R Houpt
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

3.  Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine.

Authors:  Ting Zhao; Jing Li; Yuting Fu; Hui Ye; Xiaochang Liu; Guoliang Li; Xiaolei Yang; Jingsi Yang
Journal:  NPJ Vaccines       Date:  2020-06-09       Impact factor: 7.344

4.  Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-09-21       Impact factor: 4.000

5.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

6.  Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination.

Authors:  Kasper H Kisjes; Radboud J Duintjer Tebbens; Gregory S Wallace; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

7.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

8.  Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.

Authors:  Radboud J Duintjer Tebbens; Lee M Hampton; Steven G F Wassilak; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  J Vaccines Vaccin       Date:  2016-10-03

9.  Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.

Authors:  Kimberly M Thompson; Dominika A Kalkowska; Radboud J Duintjer Tebbens
Journal:  Vaccine       Date:  2015-02-18       Impact factor: 3.641

10.  Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan.

Authors:  Dominika A Kalkowska; Radboud J Duintjer Tebbens; Mark A Pallansch; Kimberly M Thompson
Journal:  Risk Anal       Date:  2018-10-08       Impact factor: 4.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.